Positron ships PET scanner to Japan
Positron has shipped its PET scanner hardware platform, the Posicam-HZL, to the National Institute of Radiological Sciences of Japan. The equipment will be marketed and distributed by Imatron-Japan. The center will use the Posicam-HZL in oncology
Positron has shipped its PET scanner hardware platform, the Posicam-HZL, to the National Institute of Radiological Sciences of Japan. The equipment will be marketed and distributed by Imatron-Japan.
The center will use the Posicam-HZL in oncology and cardiology research, said Dr. Katsuya Yoshida of Japan's Division of Advanced Technology for Medical Imaging. Imatron-Japan president Sachiko Kinoshita said she expects interest in PET scanners to increase in that country.
Imatron, a South San Francisco-based company that creates electron beam tomography scanners, has a 16% interest in Houston-based Positron.
Positron has reported an increase in revenue for first quarter 2000 (end March 31) of 200% over the same period last year. Revenue was $1.2 million in this period compared with revenue of $388,000 for first quarter 1999. The company ascribes the increase in revenue to the shipment of one Posicam system; it did not ship any Posicam systems in the first quarter of 1999. Positron reported a net loss of $157,000 in the first quarter of 2000, which it attributed to increased staff and related operation expenditures. This was compared to net income of $34,000 in the first quarter of 1999.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.
Lunit Unveils Enhanced AI-Powered CXR Software Update
May 28th 2025The Lunit Insight CXR4 update reportedly offers new features such as current-prior comparison of chest X-rays (CXRs), acute bone fracture detection and a 99.5 percent negative predictive value (NPV) for identifying normal CXRs.
New MRI Study Questions Use of Corticosteroid Injections for Knee OA
May 27th 2025Two years after intraarticular knee injections for knee osteoarthritis (OA), study participants who had corticosteroid knee injections had greater OA progression than control patients while the use of hyaluronic acid injections was associated with less OA progression.
